- Home
- PCVX
PCVX
Vaxcyte Inc.
as 07-23-2025 4:00pm EST
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SAN CARLOS |
| Market Cap: | 4.4B | IPO Year: | 2020 |
| Target Price: | $136.50 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.98 | EPS Growth: | N/A |
| 52 Week Low/High: | $27.66 - $121.06 | Next Earning Date: | 08-05-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Vaxcyte Inc. News
PCVX Breaking Stock News: Dive into PCVX Ticker-Specific Updates for Smart Investing
Insider Monkey
2 months ago
Here’s Why Vaxcyte (PCVX) Sold Off in Q1
Insider Monkey
2 months ago
Is Vaxcyte, Inc. (PCVX) The Best Stock That Will Bounce Back?
GlobeNewswire
3 months ago
Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
3 months ago
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors
Insider Monkey
3 months ago
Is Vaxcyte, Inc. (PCVX) the Best Oversold NASDAQ Stock to Buy Right Now?
Simply Wall St.
3 months ago
Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans
Insider Monkey
3 months ago
Vaxcyte, Inc. (PCVX): Billionaire Stanley Druckenmiller’s Top Stock Pick with Huge Upside Potential
Zacks
3 months ago
Vaxcyte Stock Plummets 56% in a Month: Here's the Reason
Compare PCVX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PCVX Vaxcyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.